10x Genomics, Inc. Cash Equivalents, at Carrying Value
10x Genomics, Inc. (TXG) had Cash Equivalents, at Carrying Value of $502.51 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashEquivalentsAtCarryingValue · last filed 2026-08-07
- 2026-06-30: Cash Equivalents, at Carrying Value $502.51M.
- 2026-03-31: Cash Equivalents, at Carrying Value $490.29M.
- 2025-12-31: Cash Equivalents, at Carrying Value $473.97M.
- 2025-09-30: Cash Equivalents, at Carrying Value $432.51M.
| Period end | Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $502.51M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $490.29M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $473.97M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $432.51M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $397.71M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $377.06M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $344.07M 10-K · filed 2026-02-13 |
| 2024-09-30 | $398.16M 10-Q · filed 2024-10-29 |
| 2024-06-30 | $379.82M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $355.78M 10-Q · filed 2024-04-30 |
| 2023-12-31 | $359.28M 10-K · filed 2025-02-13 |
| 2023-09-30 | $311.26M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $325.88M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $332.32M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $219.75M 10-K · filed 2024-02-15 |
| 2022-09-30 | $233.95M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $274.19M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $312.49M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $587.45M 10-K · filed 2023-02-16 |
| 2021-09-30 | $600.44M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $621.96M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $617.20M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $663.60M 10-K · filed 2022-02-18 |
| 2020-09-30 | $768.77M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $339.84M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $372.43M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $424.17M 10-K · filed 2021-02-26 |
| 2019-09-30 | $427.44M 10-Q · filed 2019-11-12 |
| 2018-12-31 | $65.08M 10-K · filed 2020-02-27 |